Ergoteles’s Vanda Pharmaceuticals VNDA Stock Holding History

Ergoteles’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,180	Closed	-$175K	–	1652
2021 Q4	$175K	Buy	+11,180	New	+$195K	0.01%	1064

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ergoteles's VNDA Position: Q1 2022 in Review

Ergoteles sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 11,180 shares — an estimated $175K sold.

Ergoteles first reported a position in VNDA in Q4 2021 and held it in 1 quarter. The position peaked at $175K in Q4 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

Ergoteles reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 11,180 Vanda Pharmaceuticals shares in Q1 2022, an estimated $175K.
Ergoteles first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Ergoteles's Vanda Pharmaceuticals position peaked at $175K in Q4 2021.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.